Enliven Therapeutics
ELVN
ELVN
102 hedge funds and large institutions have $1.22B invested in Enliven Therapeutics in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 42 increasing their positions, 23 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
8% more capital invested
Capital invested by funds: $1.13B → $1.22B (+$88.8M)
1.77% less ownership
Funds ownership: 102.72% → 100.95% (-1.8%)
77% less call options, than puts
Call options by funds: $3K | Put options by funds: $13K
Holders
102
Holding in Top 10
8
Calls
$3K
Puts
$13K
Top Buyers
| 1 | +$15.4M | |
| 2 | +$8.2M | |
| 3 | +$8M | |
| 4 |
ABG
Ally Bridge Group
New York
|
+$6M |
| 5 |
BlackRock
New York
|
+$5.26M |
Top Sellers
| 1 | -$27.1M | |
| 2 | -$21.9M | |
| 3 | -$14.7M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$13.5M |
| 5 |
SVCM
Saturn V Capital Management
Austin,
Texas
|
-$3.56M |